pirarubicin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antineoplastics, daunorubicin derivatives | 2198 | 72496-41-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 43.20 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 57.70 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 11.10 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Bone marrow failure | 213.53 | 57.41 | 46 | 332 | 29244 | 63459400 |
| Myelosuppression | 143.09 | 57.41 | 32 | 346 | 23671 | 63464973 |
| Pleuroparenchymal fibroelastosis | 57.63 | 57.41 | 7 | 371 | 109 | 63488535 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Renal salt-wasting syndrome | 51.66 | 45.66 | 8 | 464 | 337 | 34956122 |
| Bone marrow failure | 51.48 | 45.66 | 18 | 454 | 29235 | 34927224 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Bone marrow failure | 234.06 | 38.99 | 63 | 857 | 51044 | 79692424 |
| Myelosuppression | 157.72 | 38.99 | 44 | 876 | 40252 | 79703216 |
| Pleuroparenchymal fibroelastosis | 50.94 | 38.99 | 7 | 913 | 148 | 79743320 |
| Renal salt-wasting syndrome | 47.05 | 38.99 | 8 | 912 | 708 | 79742760 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01DB08 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES Anthracyclines and related substances |
| MeSH PA | D000970 | Antineoplastic Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.11 | acidic |
| pKa2 | 9.21 | acidic |
| pKa3 | 9.92 | acidic |
| pKa4 | 11.11 | acidic |
| pKa5 | 7.5 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D01885 | KEGG_DRUG |
| C0071126 | UMLSCUI |
| CHEBI:32011 | CHEBI |
| CHEMBL2354444 | ChEMBL_ID |
| DB11616 | DRUGBANK_ID |
| C027260 | MESH_SUPPLEMENTAL_RECORD_UI |
| 5877 | INN_ID |
| D58G680W0G | UNII |
| 11296583 | PUBCHEM_CID |
| 33764 | RXNORM |
| 005780 | NDDF |
| 713434008 | SNOMEDCT_US |
Pharmaceutical products:
None